| Real-world persistence of erenumab for preventive treatment of chronic and episodic migraine: Retrospective real-world study
|
| Author(s): Jonathan Gladstone 1, Sameer Chhibber 2, Jagdeep Minhas 3, Calum S Neish 3, G Sarah Power 3, Zhiyi Lan 3, Driss Rochdi 4, Jessica Lanthier-Martel 4, Natacha Bastien 4 |
| Affiliations(s): 1Neurology, Cleveland Clinic Canada, Toronto, Ontario, Canada.
2Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada.
3Real-world Solutions, IQVIA, Kirkland, Québec, Canada.
4Neuroscience, Novartis Pharmaceuticals Canada Inc., Dorval, Québec, Canada. |
Publication(s): Headache The Journal of Head and Face Pain
PMID: 34807454 DOI: 10.1111/head.14218
|
| Document Type(s): Article, |
| Countries: Canada, |
| Click here for the abstract |
C:
Y: |
Health status & patient reported outcomes,
2022 |
|
L:
A: |
English
Clinical setting: Primary care, direct to patient research, |
|
 |
| |
| |
| Concerns, quality of life, access to care and productivity of the general population during the first 8 weeks of the coronavirus lockdown in Belgium and the Netherlands |
| Author(s): Hanne van Ballegooijen 1, Lucas Goossens 2, Ralph H Bruin 3, Renée Michels 3, Marieke Krol 3
|
| Affiliations(s): 1IQVIA, Herikerbergweg 314, 1101 CT, Amsterdam, The Netherlands. hanne.vanballegooijen@iqvia.com.
2Erasmus University Rotterdam, Erasmus School of Health Policy & Management, Rotterdam, The Netherlands.
3IQVIA, Herikerbergweg 314, 1101 CT, Amsterdam, The Netherlands. |
Publication(s): 1 IQVIA, Herikerbergweg 314, 1101 CT Amsterdam, The Netherlands. 2 Erasmus University Rotterdam, Erasmus School of Health Policy & Management, Rotterdam, The Netherlands
BMC Health Services Research (2021) 21:227
PMID: 33712010 PMCID: PMC7953179 DOI: 10.1186/s12913-021-06240-7
|
| Document Type(s): Article, |
| Countries: Netherlands , |
| Click here for the abstract |
C:
Y: |
Health economics, Health status & patient reported outcomes, Immunology and Vaccination,
2021 |
|
L:
A: |
English
Observational study, Patient questionnaire, Population Based Study, Public Health, Quality of life, Survey research, |
|
|
| |
| |
| Incorporating patient generated health data into pharmacoepidemiological research. Pharmacoepidemiology and Drug Safety. |
| Author(s): Alison Bourke 1, William G Dixon 2, Andrew Roddam 3, Kueiyu Joshua Lin 4, Gillian C Hall 5, Jeffrey R Curtis 6, Sabine N van der Veer 7, Montse Soriano-Gabarró 8, Juliane K Mills 9, Jacqueline M Major 10, Thomas Verstraeten 11, Matthew J Francis 12, Dorothee B Bartels 13 |
| Affiliations(s): 1Real World Solutions, IQVIA, London, UK.
2Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, UK.
3Data & Computational Sciences, GSK, London, UK.
4Brigham and Women's & Department of Medicine, Boston, Massachusetts, USA.
5Gillian Hall Epidemiology Ltd, London, UK.
6Division of Clinical Immunology & Rheumatology, The University of Birmingham, Birmingham, Alabama, USA.
7Centre for Health Informatics, Division of Informatics, Imaging and Data Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK.
8Bayer AG, Berlin, Germany.
9PRA Health Sciences, Raleigh, North Carolina, USA.
10Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
11P95 Pharmacovigilance and Epidemiology, Leuven, Belgium.
12The Procter & Gamble Company, Cincinnati, Ohio, USA.
13UCB Pharma, Anderlecht, Belgium. |
Publication(s): Pharmacoepidemiol Drug Saf
. 2020 Dec;29(12):1540-1549. doi: 10.1002/pds.5169. Epub 2020 Nov 13.
|
| Document Type(s): Article, |
| Countries: Belgium, Germany, UK, USA, |
| Click here for the abstract |
C:
Y: |
Database Validity and methodology, Health status & patient reported outcomes, Patient Registries & Real-World Study Methods,
2021 |
|
L:
A: |
English
Patient questionnaire, Review, |
|
|
| |
| |
| Quantifying the burden of the treatment-resistant depression in Ontario: Shredding light on an inportant mental health issue |
| Author(s): Brad Millson, G Sarah Power, Dr. Roger S. McIntyre |
| Affiliations(s): Brad Millson, G Sarah Power, IQVIA RWE team |
Publication(s): CADTH 2020
|
| Document Type(s): Article, |
| Countries: Canada, |
| Click here for the abstract |
C:
Y: |
Health status & patient reported outcomes, Mental health,
2020 |
|
L:
A: |
English
Retrospective cohort analysis, |
|
|
| |
| |
| RWE is the Future of Clinical Research: Time to Get Onboard |
| Author(s): Nancy A. Dreyer, |
| Affiliations(s): Chief Scientific Officer and Senior VP, IQVIA Real World Solutions |
Publication(s): PharmaVOICE - March 2020
|
| Document Type(s): Article, |
| Countries: USA, |
| Click here for the abstract |
C:
Y: |
Health economics, Health status & patient reported outcomes,
2020 |
|
L:
A: |
English
Economic evaluation, Literature Review, Market impact, |
|
|
| |
| |
| Considerations when evaluating real-world data quality in the context of fitness for purpose
|
| Author(s): Matthew W Reynolds 1, Alison Bourke 2, Nancy A Dreyer 3 |
| Affiliations(s): 1Real World Solutions, IQVIA, Maryland, USA.
2Real World Solutions, IQVIA United Kingdom, UK.
3Real World Solutions, IQVIA, Massachusetts, USA. |
Publication(s): Pharmacoepidemiol Drug Saf
. 2020 Oct;29(10):1316-1318. doi: 10.1002/pds.5010. Epub 2020 May 6.
|
| Document Type(s): Article, |
| Countries: UK, USA, |
| Click here for the abstract |
C:
Y: |
Health status & patient reported outcomes,
2020 |
|
L:
A: |
English
Real World Data, Real World Evidence, |
|
|
| |
| |
| Bridging the Gap Between RCTs and RWE Through Endpoint Selection
|
| Author(s): Robert J LoCasale 1, Chris L Pashos 2, Ben Gutierrez 3, Nancy A Dreyer 4, Toby Collins 5, Alan Calleja 5, Michael J Seewald 6, Jonathan M Plumb 7, Johan Liwing 8, Maurille Feudjo Tepie 9, Sajan Khosla 10 |
| Affiliations(s): 1Real World Evidence, Sanofi, Bridgewater, NJ, USA.
2AbbVie, Chicago, IL, USA.
3GSK, Philadelphia, PA, USA.
4IQVIA, Real-World Solutions, Cambridge, MA, USA.
5IQVIA, Real-World Solutions, London, UK.
6Novartis Pharma AG/Pharma Medical Affairs, Basel, Switzerland.
7Ferring Pharmaceuticals SA, St Prex, Switzerland.
8CellProtect Nordic Pharmaceuticals, Stockholm, Sweden.
9Center for Observational Research, Amgen, Cambridge, UK.
10Real-World Evidence Center of Excellence, AstraZeneca, Cambridge, UK. sajan.khosla@astrazeneca.com. |
Publication(s): Published online 2020 Jul 6. doi: 10.1007/s43441-020-00193-5
|
| Document Type(s): Article, |
| Countries: Sweden, Switzerland, UK, USA, |
| Click here for the abstract |
C:
Y: |
Health status & patient reported outcomes,
2020 |
|
L:
A: |
English
Real World Data, Real World Evidence, |
|
|
| |
| |
| The Certainty Framework for Assessing Realâ€World Data in Studies of Medical Product Safety and Effectiveness |
| Author(s): Noelle M. Cocoros Peter Arlett Nancy A. Dreyer Chieko Ishiguro Solomon Iyasu Miriam Sturkenboom Wei Zhou Sengwee Toh |
| Affiliations(s): 1Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA.
2Data Analytics and Methods Task Force, European Medicines Agency, Amsterdam, The Netherlands.
3London School of Hygiene and Tropic Medicine, London, UK.
4Center for Advanced Evidence Generation, IQVIA Real World Solutions, Cambridge, Massachusetts, USA.
5Division of Epidemiology, Office of Medical Informatics and Epidemiology, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.
6Center for Observational and Real-world Evidence, Merck & Co., Inc., Kenilworth, New Jersey, USA.
7Julius Center, Global Health, University Medical Center Utrecht, Utrecht, The Netherlands. |
Publication(s): https://doi.org/10.1002/cpt.2045
|
| Document Type(s): Article, |
| Countries: Japan, Netherlands, USA, |
| Click here for the abstract |
C:
Y: |
Health status & patient reported outcomes,
2020 |
|
L:
A: |
English
direct to patient research, Real World Data, Real World Evidence, |
|
|
| |
| |
| Dose increase beyond labelled dose of biologics is associated with incremental pharmacy costs: results from a real-world study in the UK
|
| Author(s): Anthony Bewley 1, Cristiana Miglio 2, Haijun Tian 3, Isabelle Gilloteau 4, Joannah Whitehead 5, Ruben Hermans 2 |
| Affiliations(s): 1a Whipps Cross University Hospital , London , UK.
2b IQVIA , London , UK.
3c Novartis Pharmaceuticals Corporation , East Hanover , NJ , USA.
4d Novartis Pharma AG , Novartis Campus , Basel , Switzerland.
5e Novartis UK Pharmaceuticals Ltd , Frimley, Camberley , UK. |
Publication(s): J Dermatolog Treat
. 2019 Jun;30(4):376-382. doi: 10.1080/09546634.2018.1524820. Epub 2018 Nov 19.
|
| Document Type(s): Article, |
| Countries: UK, |
| Click here for the abstract |
C:
Y: |
Dermatology, Guidelines, Health status & patient reported outcomes, Infectious disease, Infectious disease,
2019 |
|
L:
A: |
English
Burden of illness, Clinical setting: Primary care, direct-to-patient research, Observational study, |
|
|
| |
| |
| PRS72 DRUG TREATMENT PATTERNS FOR PULMONARY ARTERIAL HYPERTENSION PATIENTS IN ENGLAND: A RETROSPECTIVE ANALYSIS USING HOSPITAL TREATMENT INSIGHTS DATABASE |
| Author(s): A. Beaudet
A. Yesufu-Udechuku
E.W. Davies
L.H. Taylor
S. Sikander-Rehman
R. Ogley
F. Exposto |
| Affiliations(s): Actelion Pharmaceuticals Ltd., Allschwill, BL, Switzerland
Actelion Pharmaceuticals UK Ltd, London, UK
Actelion Pharmaceuticals Ltd., Allschwill, BL, Switzerland
IQVIA, London, UK |
Publication(s): Open ArchiveDOI:https://doi.org/10.1016/j.jval.2019.09.2561
|
| Document Type(s): Poster, |
| Countries: England, |
| Click here for the abstract |
C:
Y: |
Cardiovascular disease, Drug safety, Drug Utlization Study, Health status & patient reported outcomes,
2019 |
|
L:
A: |
English
Public Health, Real World Data, Retrospective cohort analysis, Retrospective Field Study, |
|
|
| |
| |
 1 of 4 
|
